Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 9Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Specimen Handling 3Temozolomide 2Magnetic Resonance Spectroscopy 2tipifarnib 1talazoparib 1pembrolizumab 1olaparib 1lutetium Lu 177 dotatate 1lanreotide 1copper dotatate CU-64 1Staining and Labeling 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1Biopsy 1Axitinib 16-fluorodopamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pheochromocytoma × Axitinib × Clear all
NCT03839498 2026-03-02

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Columbia University

Phase 2 Active not recruiting
6 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡